{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:18:22Z","timestamp":1762161502144},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T00:00:00Z","timestamp":1297123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>\n              <jats:italic>BCR-ABL<\/jats:italic> kinase domain (KD) mutation is the major mechanism contributing to suboptimal response to tyrosine kinase inhibitors (TKI) in <jats:italic>BCR-ABL<\/jats:italic>-positive chronic myeloid leukemia (CML) patients. T315I mutation, as one of the most frequent KD mutations, has been shown to be strongly associated with TKI resistance and subsequent therapeutic failure. A simple and sensitive method is thus required to detect T315I mutation at the earliest stage.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A single-tube allele specific-polymerase chain reaction (AS-PCR) method was developed to detect T315I mutation in a mixture of normal and mutant alleles of varying dilutions. Denaturing high performance liquid chromatography (DHPLC) and direct sequencing were performed as a comparison to AS-PCR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>T315I mutant bands were observed in the mixtures containing as low as 0.5-1% of mutant alleles by AS-PCR. The detection sensitivity of DHPLC was around 1.5-3% dilution whereas sequencing analysis was unable to detect below 6.25% dilution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>A single-tube AS-PCR is a rapid and sensitive screening method for T315I mutation. Detection of the most resistant leukemic clone in CML patients undergoing TKI therapy should be feasible with this simple and inexpensive method.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-8722-4-7","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T02:02:03Z","timestamp":1576029723000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients"],"prefix":"10.1186","volume":"4","author":[{"given":"Wanwisa","family":"Wongboonma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanna","family":"Thongnoppakhun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirayu U","family":"Auewarakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,8]]},"reference":[{"key":"141_CR1","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1053\/j.seminhematol.2006.12.007","volume":"44","author":"RH Alvarez","year":"2007","unstructured":"Alvarez RH, Kantarjian H, Cortes JE: The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol. 2007, 44: S4-14. 10.1053\/j.seminhematol.2006.12.007.","journal-title":"Semin Hematol"},{"key":"141_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0950-3536(87)80035-5","volume":"1","author":"J Groffen","year":"1987","unstructured":"Groffen J, Heisterkamp N: The BCR\/ABL hybrid gene. Baillieres Clin Haematol. 1987, 1: 983-999. 10.1016\/S0950-3536(87)80035-5.","journal-title":"Baillieres Clin Haematol"},{"key":"141_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.hoc.2004.03.003","volume":"18","author":"RL Ilaria Jr","year":"2004","unstructured":"Ilaria RL: Animal models of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004, 18: 525-543. 10.1016\/j.hoc.2004.03.003. vii","journal-title":"Hematol Oncol Clin North Am"},{"key":"141_CR4","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker BJ: Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008, 112: 4808-4817. 10.1182\/blood-2008-07-077958.","journal-title":"Blood"},{"key":"141_CR5","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/nm1009-1149","volume":"15","author":"BJ Druker","year":"2009","unstructured":"Druker BJ: Perspectives on the development of imatinib and the future of cancer research. Nat Med. 2009, 15: 1149-1152. 10.1038\/nm1009-1149.","journal-title":"Nat Med"},{"key":"141_CR6","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O'Hare","year":"2007","unstructured":"O'Hare T, Eide CA, Deininger MW: Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007, 110: 2242-2249.","journal-title":"Blood"},{"key":"141_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1756-8722-1-15","volume":"1","author":"S Cang","year":"2008","unstructured":"Cang S, Liu D: P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol. 2008, 1: 15-10.1186\/1756-8722-1-15.","journal-title":"J Hematol Oncol"},{"key":"141_CR8","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3324\/haematol.11993","volume":"93","author":"T Ernst","year":"2008","unstructured":"Ernst T, Erben P, Muller MC, Paschka P, Schenk T, Hoffmann J, Kreil S, La Rosee P, Hehlmann R, Hochhaus A: Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica. 2008, 93: 186-192. 10.3324\/haematol.11993.","journal-title":"Haematologica"},{"key":"141_CR9","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","volume":"114","author":"FE Nicolini","year":"2009","unstructured":"Nicolini FE, Mauro MJ, Martinelli G, Kim DW, Soverini S, Muller MC, Hochhaus A, Cortes J, Chuah C, Dufva IH: Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 2009, 114: 5271-5278. 10.1182\/blood-2009-04-219410.","journal-title":"Blood"},{"key":"141_CR10","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","volume":"114","author":"S Branford","year":"2009","unstructured":"Branford S, Melo JV, Hughes TP: Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?. Blood. 2009, 114: 5426-5435. 10.1182\/blood-2009-08-215939.","journal-title":"Blood"},{"key":"141_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","volume":"359","author":"N von Bubnoff","year":"2002","unstructured":"von Bubnoff N, Schneller F, Peschel C, Duyster J: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet. 2002, 359: 487-491. 10.1016\/S0140-6736(02)07679-1.","journal-title":"Lancet"},{"key":"141_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/hon.894","volume":"27","author":"SH Kim","year":"2009","unstructured":"Kim SH, Kim D, Kim DW, Goh HG, Jang SE, Lee J, Kim WS, Kweon IY, Park SH: Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. Hematol Oncol. 2009, 27: 190-197. 10.1002\/hon.894.","journal-title":"Hematol Oncol"},{"key":"141_CR13","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F: Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006, 20: 1767-1773. 10.1038\/sj.leu.2404318.","journal-title":"Leukemia"},{"key":"141_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00277-010-1039-5","volume":"90","author":"Y Qin","year":"2011","unstructured":"Qin Y, Chen S, Jiang B, Jiang Q, Jiang H, Li J, Li L, Lai Y, Liu Y, Huang X: Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann Hematol. 2011, 90: 47-52. 10.1007\/s00277-010-1039-5.","journal-title":"Ann Hematol"},{"key":"141_CR15","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","volume":"110","author":"J Cortes","year":"2007","unstructured":"Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N: Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007, 110: 4005-4011. 10.1182\/blood-2007-03-080838.","journal-title":"Blood"},{"key":"141_CR16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001, 293: 876-880. 10.1126\/science.1062538.","journal-title":"Science"},{"key":"141_CR17","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","volume":"27","author":"T Hughes","year":"2009","unstructured":"Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Muller MC, Martinelli G, Cortes J, Beppu L, Gottardi E: Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009, 27: 4204-4210. 10.1200\/JCO.2009.21.8230.","journal-title":"J Clin Oncol"},{"key":"141_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002, 2: 117-125. 10.1016\/S1535-6108(02)00096-X.","journal-title":"Cancer Cell"},{"key":"141_CR19","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","volume":"101","author":"AS Corbin","year":"2003","unstructured":"Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW: Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003, 101: 4611-4614. 10.1182\/blood-2002-12-3659.","journal-title":"Blood"},{"key":"141_CR20","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","volume":"100","author":"C Roche-Lestienne","year":"2002","unstructured":"Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, Fenaux P, Preudhomme C: Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002, 100: 1014-1018. 10.1182\/blood.V100.3.1014.","journal-title":"Blood"},{"key":"141_CR21","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW: Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006, 108: 2332-2338. 10.1182\/blood-2006-02-004580.","journal-title":"Blood"},{"key":"141_CR22","doi-asserted-by":"crossref","unstructured":"Jabbour E, Kantarjian H, Cortes J: Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?. Semin Hematol. 47: 344-353. 10.1053\/j.seminhematol.2010.06.002.","DOI":"10.1053\/j.seminhematol.2010.06.002"},{"key":"141_CR23","doi-asserted-by":"crossref","unstructured":"Wei G, Rafiyath S, Liu D: First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol. 3: 47-10.1186\/1756-8722-3-47.","DOI":"10.1186\/1756-8722-3-47"},{"key":"141_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.beha.2009.10.001","volume":"22","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Soverini S: Response definitions and European Leukemianet Management recommendations. Best Pract Res Clin Haematol. 2009, 22: 331-341. 10.1016\/j.beha.2009.10.001.","journal-title":"Best Pract Res Clin Haematol"},{"key":"141_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2353\/jmoldx.2009.080095","volume":"11","author":"D Jones","year":"2009","unstructured":"Jones D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K, Press R, Quigley N, Rothberg P, Sabath D, Viswanatha D: Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn. 2009, 11: 4-11. 10.2353\/jmoldx.2009.080095.","journal-title":"J Mol Diagn"},{"key":"141_CR26","first-page":"659","volume":"91","author":"HY Kang","year":"2006","unstructured":"Kang HY, Hwang JY, Kim SH, Goh HG, Kim M, Kim DW: Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Haematologica. 2006, 91: 659-662.","journal-title":"Haematologica"},{"key":"141_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000093641","volume":"116","author":"CU Auewarakul","year":"2006","unstructured":"Auewarakul CU, Huang S, Yimyam M, Boonmoh S: Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants. Acta Haematol. 2006, 116: 114-119. 10.1159\/000093641.","journal-title":"Acta Haematol"},{"key":"141_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-1-60327-375-6","volume-title":"Molecular Biomethods Handbook","author":"JM Walker","year":"2008","unstructured":"Walker JM, Rapley R, Leung KH, Yip SP: Denaturing High-Performance Liquid Chromatography (DHPLC) for Nucleic Acid Analysis. Molecular Biomethods Handbook. 2008, Humana Press, 89-106."},{"key":"141_CR29","doi-asserted-by":"crossref","unstructured":"Manrique Arechavaleta G, Scholl V, Perez V, Bittencourt R, Moellmann A, Hassan R, Seuanez HN, Dobbin J, Martinez L, Renault IZ, Uriarte R: Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors. Clin Exp Med. 11: 55-59. 10.1007\/s10238-010-0101-x.","DOI":"10.1007\/s10238-010-0101-x"},{"key":"141_CR30","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/sj.leu.2403307","volume":"18","author":"MW Deininger","year":"2004","unstructured":"Deininger MW, McGreevey L, Willis S, Bainbridge TM, Druker BJ, Heinrich MC: Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia. 2004, 18: 864-871. 10.1038\/sj.leu.2403307.","journal-title":"Leukemia"},{"key":"141_CR31","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1373\/clinchem.2004.031112","volume":"50","author":"S Soverini","year":"2004","unstructured":"Soverini S, Martinelli G, Amabile M, Poerio A, Bianchini M, Rosti G, Pane F, Saglio G, Baccarani M: Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem. 2004, 50: 1205-1213. 10.1373\/clinchem.2004.031112.","journal-title":"Clin Chem"},{"key":"141_CR32","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3324\/haematol.2009.006981","volume":"94","author":"T Ernst","year":"2009","unstructured":"Ernst T, Gruber FX, Pelz-Ackermann O, Maier J, Pfirrmann M, Muller MC, Mikkola I, Porkka K, Niederwieser D, Hochhaus A, Lange T: A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. Haematologica. 2009, 94: 1227-1235. 10.3324\/haematol.2009.006981.","journal-title":"Haematologica"},{"key":"141_CR33","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1373\/clinchem.2004.047274","volume":"51","author":"N Sorel","year":"2005","unstructured":"Sorel N, Chazelas F, Brizard A, Chomel JC: Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients. Clin Chem. 2005, 51: 1263-1266. 10.1373\/clinchem.2004.047274.","journal-title":"Clin Chem"},{"key":"141_CR34","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","volume":"106","author":"SG Willis","year":"2005","unstructured":"Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B: High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 2005, 106: 2128-2137. 10.1182\/blood-2005-03-1036.","journal-title":"Blood"},{"key":"141_CR35","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/sj.leu.2404635","volume":"21","author":"A Vivante","year":"2007","unstructured":"Vivante A, Amariglio N, Koren-Michowitz M, Ashur-Fabian O, Nagler A, Rechavi G, Cohen Y: High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations. Leukemia. 2007, 21: 1318-1321. 10.1038\/sj.leu.2404635.","journal-title":"Leukemia"},{"key":"141_CR36","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F: Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009, 27: 6041-6051. 10.1200\/JCO.2009.25.0779.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-4-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1756-8722-4-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-4-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T12:45:35Z","timestamp":1630500335000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-4-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["141"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-4-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,8]]},"assertion":[{"value":"4 January 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"7"}}